The short version of Aib substitution fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-31 and is reviewed periodically as new material appears.
Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
| Property | Value | Notes |
|---|---|---|
| Typical purity threshold | 95 percent or greater by HPLC area | common specification for research-grade peptide |
| Primary separation method | Reversed-phase HPLC | resolves related peptides and oxidation products |
| Identity confirmation | Electrospray mass spectrometry | observed mass compared with theoretical mass |
| Common degradation products | Deamidated and oxidised variants | form during synthesis and during storage |
| Preferred container | Low-binding polypropylene | reduces adsorption of dilute solutions |
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
In what could be the first global scientific analysis of plastic pollution of lakes and reservoirs that is not limited to recently increasingly studied microplastics, a large team of researchers reports high prevalence and vulnerability factors. In what could be the first global scientific analysis of agricultural pesticide pollution, scientists report that of the studied third of the three million metric tons of pesticides used annually, ~10% remains as toxic residue in soil while rivers receive at least 730 tons where they nearly do not degrade. A study suggests chemical alternatives to age reversal via Yamanaka factors gene therapy are feasible via early in vitro fibroblasts data. On 3 July, researchers report subcutaneous administration of longevity factor α-klotho enhanced cognition in old rhesus macaques. On 27 July, a study shows rejuvenation effects in mice from heterochronic parabiosis endure after the joined mice are detached.
Its main geographical units are: the Coastal Plain along the Gulf of Guinea, the Ashanti uplands in the centre, the Volta Basin in the east, which is dominated by Lake Volta, and the Northern Plains stretching to Burkina Faso. The highest point is Mount Afadja (885 m) in the Akwapim-Togo Range. The northernmost settlement in Ghana is Pulmakong near the Burkina Faso border, while the southernmost point is Cape Three Points.
== Industry references == These terms generally apply broadly across industries and institutions. In addition, they may have very specific meanings and requirements for specific products, regulations, and industries. Some examples:
Biochemistry is the study of the chemical substances and vital processes occurring in live organisms. Biochemists focus heavily on the role, function, and structure of bio-molecules. The study of the chemistry behind biological processes and the synthesis of biologically active molecules are applications of biochemistry. Biochemistry studies life at the atomic and molecular level. Genetics is the study of the effect of genetic differences in organisms. This can often be inferred by the absence of a normal component (e.g. one gene). The study of "mutants" – organisms that lack one or more functional components with respect to the so-called "wild type" or normal phenotype. Genetic interactions (epistasis) can often confound simple interpretations of such "knockout" studies. Molecular biology is the study of molecular underpinnings of the biological phenomena, focusing on molecular synthesis, modification, mechanisms and interactions. The central dogma of molecular biology, where genetic material is transcribed into RNA and then translated into protein, despite being oversimplified, still provides a good starting point for understanding the field. This concept has been revised in light of emerging novel roles for RNA. Chemical biology seeks to develop new tools based on small molecules that allow minimal perturbation of biological systems while providing detailed information about their function.
=== Other conditions === Previous hand injury Ledderhose disease (plantar fibromatosis) Epilepsy (possibly due to anti-convulsive medication) Higher-than-average fasting blood glucose level Diabetes mellitus HIV Macrophallism Previous myocardial infarction
Sources: en.wikipedia.org
Traditionally in composite science a strong interface between the matrix and filler is required to achieve favorable mechanical properties. If this is not the case, the phases tend to separate along the weak interface and makes for very poor mechanical properties. In a MCC composite however this is not the case, if the interaction between the filler and matrix is stronger than the filler-filler interaction the mechanical strength of the composite is noticeably decreased. Difficulties in natural fiber nanocomposites arise from dispersity and the tendency small fibers to aggregate in the matrix. Because of the high surface area to volume ratio the fibers have a tendency to aggregate, more so than in micro-scale composites. Additionally secondary processing of collagen sources to obtain sufficient purity collagen micro fibrils adds a degree of cost and challenge to creating a load bearing cellulose or other filler based nanocomposite.
Citalopram, sold under the brand name Celexa among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is used to treat major depressive disorder, obsessive–compulsive disorder, panic disorder, and social anxiety disorder. The antidepressant effects may take one to four weeks to occur. It is typically taken orally (swallowed by mouth). In some European countries, it is sometimes given intravenously (injected into a vein) to initiate treatment, before switching to the oral route of administration for continuation of treatment. It has also been used intravenously in other parts of the world in some other circumstances. Common side effects include nausea, trouble sleeping, sexual problems, shakiness, feeling tired, and sweating. In some patients, sexual dysfunction may persist even after the drug is discontinued, a condition known as post-SSRI sexual dysfunction; regulatory agencies including the European Medicines Agency and Health Canada have recommended that citalopram's product labeling warn of this risk. Serious side effects include an increased risk of suicide in those under the age of 25, serotonin syndrome, glaucoma, and QT prolongation. Citalopram was approved for medical use in the United States in 1998. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2023, it was the 43rd most commonly prescribed medication in the United States, with more than 14 million prescriptions.
As of January 2022, the World Health Organization recommends baricitinib for people with severe or critical COVID-19. Thereafter in February 2022, an exploratory randomized, placebo-controlled trial of participants receiving invasive mechanical ventilation or extracorporeal membrane oxygenation were randomly to baricitinib or placebo. There was a 46% statistically significant relative reduction in all-cause mortality for participants receiving baricitinib compared to those receiving placebo at 28 days which was sustained at 60 days. In March 2022, the RECOVERY trial reported that the use of baricitinib cut the risk of death by about a fifth in about 12,000 participants. Then in May 2022, the FDA approved use of baricitinib for the treatment of adults hospitalized with COVID-19 who require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation with a recommended dose of 4 mg once daily for 14 days or until hospital discharge, whichever happens first.
15 July – Six members of the environmental protest group, Climate Camp Scotland, are arrested after the group occupies the Ineos gas power station at Grangemouth oil refinery. 16 July – A pod of 55 pilot whales dies after becoming stranded at Traigh Mhor beach at North Tolsta on the Isle of Lewis. 19 July – Police launch an operation to remove climate change protestors from Grangemouth Refinery, making 11 arrests. 21 July – Police Scotland confirms that climate change protestors have ended their demonstrations at two oil refineries at Grangemouth and Clydebank. 22 July – Four climate change protestors are arrested at Grangemouth after chaining themselves to an old washing machine. 25 July Following a trial at the High Court in Glasgow, Connor Gibson, 20, is found guilty of the sexual assault and murder of his 16-year-old sister, Amber Gibson, in November 2021. Stephen Corrigan, unknown to the siblings, is convicted of concealing the body. The Scottish Government approves a £500m plan to expand Argyll's Hollow Mountain underground power station. 26 July – The Scottish COVID-19 Inquiry begins, with its opening hearing taking place in Dundee. 27 July – First Minister Humza Yousaf unveils a new Scottish Government paper on independence that includes plans for Scottish citizenship and passports. 28 July – Glasgow Life confirms it has cancelled the 2023 Bonfire Night event usually held on Glasgow Green and has no plans to hold any similar events in future.
Sources: en.wikipedia.org
Radiation protection continued to develop with the invention of new measuring devices such as the chromoradiometer by Guido Holzknecht (1872-1931) in 1902, the radiometer by Raymond Sabouraud (1864-1938) and Henri Noiré (1878–1937) in 1904/05, and the quantimeter by Robert Kienböck (1873-1951) in 1905, which made it possible to determine maximum doses at which there was a high probability that no skin changes would occur. Radium was also included by the British Roentgen Society, which published its first memorandum on radium protection in 1921.
One major function of platelets is to contribute to hemostasis: the process of stopping bleeding at the site where the lining of vessels (endothelium) has been interrupted. Platelets gather at the site and, unless the interruption is physically too large, they plug it. First, platelets attach to substances outside the interrupted endothelium: adhesion. Second, they change shape, turn on receptors and secrete chemical messengers: activation. Third, they connect to each other through receptor bridges: aggregation. Formation of this platelet plug (primary hemostasis) is associated with activation of the coagulation cascade, with resultant fibrin deposition and linking (secondary hemostasis). These processes may overlap: the spectrum is from a predominantly platelet plug, or "white clot" to a predominantly fibrin, or "red clot" or the more typical mixture. Berridge adds retraction and platelet inhibition as fourth and fifth steps, while others would add a sixth step, wound repair. Platelets participate in both innate and adaptive intravascular immune responses. In addition to facilitating the clotting process, platelets contain cytokines and growth factors which can promote wound healing and regeneration of damaged tissues.
Pappalysin-1, also known as pregnancy-associated plasma protein A, and insulin-like growth factor binding protein-4 protease is a protein encoded by the PAPPA gene in humans. PAPPA is a secreted protease whose main substrate is insulin-like growth factor binding proteins. Pappalysin-1 is also used in screening tests for Down syndrome.
Sources: en.wikipedia.org
Different techniques detect different classes of impurities, so a single number does not describe a sample completely. Reversed-phase chromatography resolves related peptides well but can miss inorganic salts, while mass spectrometry confirms mass without quantifying everything present. Comparing results requires knowing which method was used and how it was validated.
Cycling between frozen and liquid states can promote aggregation and surface adsorption at the container wall. Each cycle exposes the peptide to transient concentration and pH shifts near the ice interface. Aliquoting before storage limits the number of cycles a single container experiences.
Purity describes how much of the material is the intended substance, while identity describes whether that substance is the correct molecule. Mass spectrometry gives an observed mass that is compared with the theoretical value for the sequence. Peptide mapping after digestion adds sequence-level confirmation that mass alone cannot provide.
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.